Preserved High Probability of Overall Survival with Significant Reduction of Chemotherapy for Myeloid Leukemia in Down Syndrome: A Nationwide Prospective Study in Japan

Targeting the wee1 kinase for treatment of pediatric Down syndrome acute myeloid leukemia

(2014) J. Timothy Caldwell et al.   PEDIATRIC BLOOD & CANCER

Normal karyotype is a poor prognostic factor in myeloid leukemia of Down syndrome: a retrospective, international study

(2013) M. Blink et al.   HAEMATOLOGICA

Histone deacetylase inhibitors induce apoptosis in myeloid leukemia by suppressing autophagy

(2013) M V Stankov et al.   LEUKEMIA

Clinical characteristics and outcome of refractory/relapsed myeloid leukemia in children with Down syndrome

(2012) T. Taga et al.   BLOOD

Favorable survival maintained in children who have myeloid leukemia associated with Down syndrome using reduced-dose chemotherapy on Children's Oncology Group trial A2971

(2012) April D. Sorrell et al.   CANCER

Identification of Regulators of Polyploidization Presents Therapeutic Targets for Treatment of AMKL

(2012) Qiang Wen et al.   CELL

Continuous and high-dose cytarabine combined chemotherapy in children with down syndrome and acute myeloid leukemia: Report from the Japanese children's cancer and leukemia study group (JCCLSG) AML 9805 down study

(2010) Takashi Taga et al.   PEDIATRIC BLOOD & CANCER

Mutations of GATA1, FLT3, MLL-partial tandem duplication, NRAS, and RUNX1 genes are not found in a 7-year-old Down syndrome patient with acute myeloid leukemia (FAB-M2) having a good prognosis

(2007) Machiko Kawamura et al.   CANCER GENETICS AND CYTOGENETICS